Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same

Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same

US Patent 8053556 · Granted Nov 8, 2011

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Information management apparatus and non-transitory computer-readable recording 2025
Adhesive film and flexible printed circuit board2025
Anti-GPC3 antibody2024
Anti-GPC3 antibody2023
T-cell receptor2023
Anti-GPC3 antibody2020
CDCA1 epitope peptides for Th1 cells and vaccines containing the same2019
KIF20A epitope peptides for TH1 cells and vaccines containing the same2019
Transmission device and signal processing method2018
IMP-3 epitope peptides for TH1 cells and vaccines containing the same2017
CDCA1 epitope peptides for Th1 cells and vaccines containing the same2017
LY6K epitope peptides for TH1 cells and vaccines containing the same2017